Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan S Coates

Showing results (11-20 of 106) with videos related to

Pageof 11
Sort By:
Lancet (London, England)|September 27, 2005
Relation between chemotherapy dose, oestrogen receptor expression, and body-mass indexMarco Colleoni, Sigui Li, Richard D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93, Olivia Pagani, Shari Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93, Marco Colleoni, Shari Gelber, et al.
Breast Cancer Research and Treatment|July 17, 2008
Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution seriesGiuseppe Viale, Nicole Rotmensz, Patrick Maisonneuve, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2007
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93, Marco Colleoni, Shari Gelber, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VIIPer Karlsson, Bernard F Cole, Karen N Price, et al.
Journal of the National Cancer Institute|December 18, 2003
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial, Monica Castiglione-Gertsch, Anne O'Neill, et al.
Breast Cancer Research and Treatment|September 6, 2011
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopauseJacquie Chirgwin, Zhuoxin Sun, Ian Smith, et al.
Cancer|February 25, 2003
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?Helen Trihia, Susan Murray, Karen Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to VMarco Colleoni, Zhuoxin Sun, Karen N Price, et al.
Pageof 11

Showing results (11-20 of 106) with videos related to

Sort By:
Pageof 11
Lancet (London, England)|September 27, 2005
Relation between chemotherapy dose, oestrogen receptor expression, and body-mass indexMarco Colleoni, Sigui Li, Richard D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93, Olivia Pagani, Shari Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93, Marco Colleoni, Shari Gelber, et al.
Breast Cancer Research and Treatment|July 17, 2008
Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution seriesGiuseppe Viale, Nicole Rotmensz, Patrick Maisonneuve, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2007
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93, Marco Colleoni, Shari Gelber, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VIIPer Karlsson, Bernard F Cole, Karen N Price, et al.
Journal of the National Cancer Institute|December 18, 2003
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial, Monica Castiglione-Gertsch, Anne O'Neill, et al.
Breast Cancer Research and Treatment|September 6, 2011
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopauseJacquie Chirgwin, Zhuoxin Sun, Ian Smith, et al.
Cancer|February 25, 2003
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?Helen Trihia, Susan Murray, Karen Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to VMarco Colleoni, Zhuoxin Sun, Karen N Price, et al.
Pageof 11